We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tenet Healthcare (THC) to Divest Operations to Amedisys
Read MoreHide Full Article
Tenet Healthcare Corporation (THC - Free Report) recently announced that it has inked a deal with Amedisys, Inc. (AMED - Free Report) to divest its Home Health and Hospice operations in Arizona, Illinois, Massachusetts and Texas to the latter.
Tenet Healthcare regularly divests unprofitable non-core operations to remain focused on the primary business. Prior to the aforesaid deal, the company sold five of its hospitals to WellStar Health System in Apr 2016. Previous to that, in Nov 2015, the company sold two hospitals and 19 physician groups in North Carolina to Duke LifePoint and also divested St. Louis University Hospital to SSM Health.
Such business moves reflect the company’s effective evaluation of the feasibility of building integrated delivery networks and assessment of its market share. Tenet Healthcare has also divested hospitals in markets with little or no chance of growth.
We note that Tenet Healthcare stock has found favor with investors in recent times. The company’s business strategies seem to have started bearing fruit as its shares have outperformed the broader Medical-Hospitals industry in the last three months. Shares of the company gained 26% compared 19.5% increase of the industry over this period.
Tenet Healthcare has already strengthened its position in the markets by consistently improving the quality of its services to patients. As a result, the buyout will immensely benefit Amedisys. The acquirer, which is committed to serving patients, employees and the community, will be able to deliver premium quality home health and hospice services as well as post-acute services in the key markets of the concerned regions.
We expect to hear more divestiture news from the company as it recently indicated that it is pursuing the sale of additional hospitals and exiting its health plan business in 2017
Aeterna Zentaris delivered positive surprise in the last four quarters with an average beat of 31.7%.
Applied Genetic Technologies also delivered positive surprises in the last four quarters with an average beat of 222.92%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Tenet Healthcare (THC) to Divest Operations to Amedisys
Tenet Healthcare Corporation (THC - Free Report) recently announced that it has inked a deal with Amedisys, Inc. (AMED - Free Report) to divest its Home Health and Hospice operations in Arizona, Illinois, Massachusetts and Texas to the latter.
Tenet Healthcare regularly divests unprofitable non-core operations to remain focused on the primary business. Prior to the aforesaid deal, the company sold five of its hospitals to WellStar Health System in Apr 2016. Previous to that, in Nov 2015, the company sold two hospitals and 19 physician groups in North Carolina to Duke LifePoint and also divested St. Louis University Hospital to SSM Health.
Such business moves reflect the company’s effective evaluation of the feasibility of building integrated delivery networks and assessment of its market share. Tenet Healthcare has also divested hospitals in markets with little or no chance of growth.
We note that Tenet Healthcare stock has found favor with investors in recent times. The company’s business strategies seem to have started bearing fruit as its shares have outperformed the broader Medical-Hospitals industry in the last three months. Shares of the company gained 26% compared 19.5% increase of the industry over this period.
Tenet Healthcare has already strengthened its position in the markets by consistently improving the quality of its services to patients. As a result, the buyout will immensely benefit Amedisys. The acquirer, which is committed to serving patients, employees and the community, will be able to deliver premium quality home health and hospice services as well as post-acute services in the key markets of the concerned regions.
We expect to hear more divestiture news from the company as it recently indicated that it is pursuing the sale of additional hospitals and exiting its health plan business in 2017
Zacks Rank and Stocks to Consider:
Tenet Healthcare presently carries Zacks Rank #3 (Hold).
Some better-ranked stocks from the medical sector include Aeterna Zentaris Inc.
(AEZS - Free Report) and Applied Genetic Technologies Corporation . Both of these stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Aeterna Zentaris delivered positive surprise in the last four quarters with an average beat of 31.7%.
Applied Genetic Technologies also delivered positive surprises in the last four quarters with an average beat of 222.92%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>